HTML has links - PDF has Authentication
182-50-015  <<  182-50-025 >>   182-50-030

PDFWAC 182-50-025

Membership and qualifications of pharmacy and therapeutics committee.

(1) The committee consists of no fewer than ten members appointed by the appointing authority.
(2) The appointing authority has the sole right to appoint committee members and may terminate appointment of any member at any time during the term.
(3) The appointing authority makes appointments to the committee from a pool of interested applicants. Interested people are provided an opportunity to submit applications to the appointing authority.
(4) Members enter into an agreement with the health care authority at the time of their appointment to the committee and act in accordance with all of its terms and conditions. Failure to do so may result in termination of the appointment.
(5) The membership composition at all times is consistent with applicable federal requirements for its drug utilization review board under the federal Social Security Act, Title 19 Sec. 1927 and the requirements of the health care authority. Pharmacists and physicians each represent at least thirty-one percent, but no more than fifty-one percent of committee membership respectively.
(6) Members must be actively practicing in their clinical area of expertise throughout the entire term of their appointments.
(7) Members must have knowledge and expertise in one or more of the following:
(a) Clinically appropriate prescribing of covered outpatient drugs;
(b) Clinically appropriate dispensing and monitoring of covered outpatient drugs;
(c) Drug use review;
(d) Medical quality assurance;
(e) Disease state management; or
(f) Evidence-based medicine.
(8) Members of the committee must not be employed by a pharmaceutical manufacturer, a pharmacy benefits management company, or by any state agency administering state purchased health care programs during their terms and must not have been so employed for eighteen months prior to their appointment.
(9) A member must not have a substantial financial conflict of interest including any interest in any pharmaceutical company, including the holding of stock options or the receipt of honoraria or consultant moneys. The appointing authority in its sole discretion may disqualify any potential member if it determines that a substantial conflict of interest exists.
(10) As part of the application process, prospective committee members must complete a conflict of interest disclosure form, provided by the appointing authority, and after appointment, annually by July 1st of each year. Members must keep their disclosure statements current and provide updated information whenever circumstances change.
(11) Committee members must agree to keep all proprietary information confidential.
[Statutory Authority: RCW 41.05.021, 41.05.160, and 69.41.190. WSR 16-16-083, § 182-50-025, filed 7/29/16, effective 8/29/16. Statutory Authority: RCW 41.05.160; 2004 1st sp.s. c 29 § 10. WSR 04-06-021 (Order 03-02), § 182-50-025, filed 2/23/04, effective 3/25/04.]
Site Contents
Selected content listed in alphabetical order under each group